Vexxa Lifesciences Pvt. Ltd. — Imipenem Exporter Profile
Indian Pharmaceutical Exporter · #7 for Imipenem · $348.2K export value · DGFT Verified
Vexxa Lifesciences Pvt. Ltd. is the #7 Indian exporter of Imipenem with $348.2K in export value and 38 verified shipments. Vexxa Lifesciences Pvt. Ltd. holds a 1.0% market share in Imipenem exports across 3 countries.
Vexxa Lifesciences Pvt. Ltd. — Imipenem Export Profile: Buyers & Destinations
Where Does Vexxa Lifesciences Pvt. Ltd. Export Imipenem?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PHILIPPINES | $493.7K | 61 | 95.8% |
| MYANMAR | $18.0K | 4 | 3.5% |
| THAILAND | $3.6K | 2 | 0.7% |
Vexxa Lifesciences Pvt. Ltd. exports Imipenem to 3 countries. The largest destination is PHILIPPINES accounting for 95.8% of Vexxa Lifesciences Pvt. Ltd.'s Imipenem shipments, followed by MYANMAR (3.5%) and THAILAND (0.7%). These destinations reflect Vexxa Lifesciences Pvt. Ltd.'s established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Imipenem from Vexxa Lifesciences Pvt. Ltd.?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| VE PHARMA INC | PHILIPPINES | $434.2K | 45 |
| VE PHARMA INC. | PHILIPPINES | $59.5K | 16 |
| ASHRO MYANMAR LIMITED | MYANMAR | $16.2K | 3 |
| PAING HEIN KYAW COMPANY LIMITED | MYANMAR | $5.4K | 3 |
Vexxa Lifesciences Pvt. Ltd. supplies Imipenem to 4 buyers globally. The largest buyer is VE PHARMA INC (PHILIPPINES), followed by VE PHARMA INC. (PHILIPPINES) and ASHRO MYANMAR LIMITED (MYANMAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Imipenem Export Value and How Much Does Vexxa Lifesciences Pvt. Ltd. Contribute?
India exported $20.1M worth of Imipenem through 803 shipments from 140 suppliers to 94 countries, serving 302 buyers globally. Vexxa Lifesciences Pvt. Ltd. contributes $348.2K to this total, accounting for 1.0% of India's Imipenem exports. Vexxa Lifesciences Pvt. Ltd. ships Imipenem to 3 countries through 4 buyers.
What Is the Average Shipment Value for Vexxa Lifesciences Pvt. Ltd.'s Imipenem Exports?
Vexxa Lifesciences Pvt. Ltd.'s average Imipenem shipment value is $9.2K per consignment, based on 38 shipments totaling $348.2K. The largest destination is PHILIPPINES (95.8% of Vexxa Lifesciences Pvt. Ltd.'s Imipenem exports).
How Does Vexxa Lifesciences Pvt. Ltd. Compare to Other Indian Imipenem Exporters?
Vexxa Lifesciences Pvt. Ltd. ranks #7 among 140 Indian Imipenem exporters with a 1.0% market share. The top 3 exporters are VENUS REMEDIES LIMITED ($9.7M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($6.0M), PROTECH BIO SYSTEMS PRIVATE LIMITED ($950.0K). Vexxa Lifesciences Pvt. Ltd. processed 38 shipments to 3 destination countries.
What Imipenem Formulations Does Vexxa Lifesciences Pvt. Ltd. Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| Vexpinem 500 (IMIPENEM + CILASTATIN INJ) | $168.2K | 25 |
| Vexpinem 500 Inj (IMIPENEM + CILASTATININJ) BATCH NO-X4KB013F MFG DT-NOV-2024 EXP DT-OCT-2026 | $63.1K | 2 |
| Vexpinem 500 IMIPENEM + CILASTATIN INJBCH NO-X3FB063C MANUFACTURING DT-JUN-2023 EXP DT-MAY-2025 | $50.7K | 8 |
| Vexpinem 500 IMIPENEM + CILASTATIN INJBCH NO-X3GB113B MANUFACTURING DT-JUL-2023 EXP DT-JUN-2025 | $31.5K | 4 |
| VEXPINEM 500 INJ (IMIPENEM + CILASTATININJ) BCH NO-X4DB013C MFG DT-APR-2024 EXP DT-MAR-2026 | $27.7K | 1 |
| VEXPINEM 500 (IMIPENEM + CILASTATIN INJ | $21.1K | 1 |
| VEXPINEM 500 INJ (IMIPENEM + CILASTATININJ) BCH NO-X3IB103C MFG DT-SEP-2023 EXPDT-AUG-2025 | $16.8K | 1 |
| Vexpinem 500 Inj (IMIPENEM + CILASTATININJ) BATCH NO-X4LB023C MFG DT-DEC-2024 EXP DT-NOV-2026 | $15.9K | 1 |
| IMIPENEM AND CILASTATIN FOR INJECTION USP 500MG 10ML ECH VL CONT IMIPENEM USPEQV TO ANHYDROUS IMIPENEM 500MG CILASTAT | $13.5K | 1 |
| IMIPENEM AND CILASTATIN FOR INJECTION U S P 500MG 10ML VEXPINEM 500MG BATCH NO X5CB023F MFG DT MAR 2025 EXP DT FEB 20 | $13.4K | 1 |
Vexxa Lifesciences Pvt. Ltd. exports 24 distinct Imipenem formulations including tablets, capsules, syrups, and combination drugs. The top formulation is Vexpinem 500 (IMIPENEM + CILASTATIN INJ) with 25 shipments worth $168.2K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Vexxa Lifesciences Pvt. Ltd. Compare to Nearest Imipenem Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | SWISS PARENTERALS LIMITED | $450.0K | 9 | 6 | $50.0K |
| 6 | M J BIOPHARM PRIVATE LIMITED | $450.0K | 9 | 2 | $50.0K |
| 7 | VEXXA LIFESCIENCES PVT. LTD. ★ | $348.2K | 38 | 3 | $9.2K |
| 9 | KWALITY PHARMACEUTICALS LIMITED | $324.4K | 18 | 4 | $18.0K |
| 10 | MARKSANS PHARMA LIMITED | $236.5K | 8 | 1 | $29.6K |
Vexxa Lifesciences Pvt. Ltd. ranks #7 among 140 Indian Imipenem exporters. Average shipment value of $9.2K compared to the market average of $143.4K. The closest competitors by value are SWISS PARENTERALS LIMITED and M J BIOPHARM PRIVATE LIMITED.
Which Indian Ports Ship Imipenem Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 114 | 14.2% |
| DELHI AIR | 83 | 10.3% |
| SAHAR AIR | 76 | 9.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 57 | 7.1% |
| NHAVA SHEVA SEA (INNSA1) | 37 | 4.6% |
| Delhi Air | 34 | 4.2% |
| DHANNAD ICD | 30 | 3.7% |
| DHANNAD ICD (INDHA6) | 27 | 3.4% |
Market Intelligence
Latest developments and market context
Detailed market intelligence for Imipenem — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Imipenem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Vexxa Lifesciences Pvt. Ltd. matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 67 individual customs records matching Vexxa Lifesciences Pvt. Ltd. exporting Imipenem, covering 24 formulations to 3 countries via 4 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 94+ countries, 302+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Imipenem Export Data from Vexxa Lifesciences Pvt. Ltd.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Vexxa Lifesciences Pvt. Ltd.'s Imipenem exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Vexxa Lifesciences Pvt. Ltd.
Company Profile
0 products · $0 total trade · 0 categories
Imipenem Stats
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Vexxa Lifesciences Pvt. Ltd..
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Imipenem. For current shipment-level data, contact TransData Nexus.